Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics ( CRSP ) : Can the Stock Really Move This High?
The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
https://www.zacks.com/stock/news/2365318/wall-street-analysts-see-a-6275-upside-in-crispr-therapeutics-crsp-can-the-stock-really-move-this-high